German healthcare reform: what’s the impact on Europe’s pharmaceutical industry?
Germany, one of the most attractive EU markets for pharmaceuticals and often the first-to-launch market for innovative therapies in Europe is adopting cost-containment measures that will negatively impact the industry and all relevant stakeholders. Germany has a healthcare model where the majority of the German population (approximately 90% or 70 million citizens) are insured via […]